English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduIRIC obtains $583,654 from the Quebec government for the integration of a new cell painting technology that holds great promise for drug discovery.
Tag: Drug Discovery
Dark matter, neutrinos and drug discovery: how AI is powering SLAC science and technology
Check out the second of a two-part series exploring how artificial intelligence helps researchers from around the world perform cutting-edge science with the lab’s state-of-the-art facilities and instruments. Read part one here. In this part you’ll learn how AI is playing a key role in helping SLAC researchers find new galaxies and tiny neutrinos, and discover new drugs.
A New Approach to Predicting Malaria Drug Resistance
Researchers at UC San Diego analyzed the genomes of hundreds of malaria parasites to determine which genetic variants are most likely to confer drug resistance.
Data Scientist Fixes His Sights on Speeding Up Drug Discovery
Scientists are using artificial intelligence and powerful computing to sculpt new molecules in an effort to treat disease.
Game-Changing Quantum Chemistry Calculations on Frontier Earn Gordon Bell Prize
This year’s Association for Computing Machinery’s Gordon Bell Prize in supercomputing goes to researchers led by the University of Melbourne who used the Frontier supercomputer to conduct a quantum molecular dynamics simulation 1,000 times greater in size and speed than any previous simulation of its kind.The team also includes researchers from AMD, QDX, and the Department of Energy’s Oak Ridge National Laboratory.
Argonne to explore novel ways to fight cancer and transform vaccine discovery with over $21 million from ARPA-H
Argonne has received up to $21 million from ARPA-H to use AI and supercomputing in two projects: one targeting hard-to-treat tumors, and another aiming to create vaccines for multiple viral threats, including cancer and pandemics.
Are Biologics the Future of Food Allergy Treatment? One Study Weighs Pros and Cons
Publishing in Annals of Allergy, Asthma and Immunology, UNC School of Medicine researchers delve into the perspectives of community and academic providers on the role of biologics and food allergy. This study was led by co-authors Edwin Kim, MD, Division Chief of Pediatric Allergy and Immunology, and Jill Fisher, PhD, professor in the UNC Department of Social Medicine and Center for Bioethics.
ReadCube expands literature management with new AI Assistant and comprehensive search
Digital Science announces the AI-powered ReadCube Pro, offering researchers new tools to simplify and accelerate literature management and literature monitoring workflows.
Osmo Announces Launch of Scientific Advisory Board
The digital olfaction company, Osmo, today announced the formation of its Scientific Advisory Board (SAB) composed of leading experts in synthetic chemistry, analytical chemistry, artificial intelligence and sensor technology, to help propel the company’s olfactory innovation across scent detection, digitization and creation.
PA State Senator Aument Recognized for His Support of Research at SHRO
Temple University’s Sbarro Institute for Cancer Research and Molecular Medicine has benefited from the support of Pennsylvania State Sen. Ryan Aument since he took office in 2014.
New AI Tool Captures How Proteins Behave in Context
In a marked advance over current AI models, the new approach captures how proteins act not in isolation but in their cellular and tissue environments.
Indagar en la mente de la inteligencia artificial para fabricar mejores antibióticos
La inteligencia artificial (IA) ha explotado en popularidad, pero al igual que un ser humano, es difícil leer la mente de la IA. La IA explicable (XAI), un subconjunto de la tecnología, podría ayudarnos a hacer justamente eso justificando las decisiones de un modelo.
Peering into the mind of artificial intelligence to make better antibiotics
Artificial intelligence (AI) has exploded in popularity, but it’s hard to know what’s going on inside. Explainable AI (XAI) gives justification for an AI model’s decisions, and now, researchers are using it to make better antibiotics. They will present their results at ACS Fall 2024.
Advanced AI-Based Techniques Scale-up Solving Complex Combinatorial Optimization Problems
A framework based on advanced AI techniques can solve complex, computationally intensive problems faster and in a more more scalable way than state-of-the-art methods, according to a study led by engineers at the University of California San Diego. In the paper, which was published May 30 in Nature Machine Intelligence, researchers present HypOp, a framework that uses unsupervised learning and hypergraph neural networks.
Groundbreaking LLNL and BridgeBio Oncology Therapeutics collaboration announces start of human trials for supercomputing-discovered cancer drug
In a substantial milestone for supercomputing-aided drug design, Lawrence Livermore National Laboratory (LLNL) and BridgeBio Oncology Therapeutics (BridgeBio) today announced clinical trials have begun for a first-in-class medication that targets specific genetic mutations implicated in many types of cancer.
Innovative Techniques Open New Avenues in Drug Discovery for Brain Diseases
Volume 29, Issue 2 of SLAS Discovery features two review articles, six original research articles covering phenotypic screening perspectives, medulloblastoma therapies and interventions for neurodegenerative diseases.
Researchers Wrestle with Accuracy of AI Technology Used to Create New Drug Candidates
Researchers at the UNC School of Medicine, UCSF, Stanford, and Harvard determined that a protein prediction technology can yield accurate results in the hunt to efficiently find the best possible drug candidates for many conditions.
MD Anderson Research Highlights for May 8, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
GUIDE team develops computational approach to redesign antibodies for broader effectiveness against viral pandemics
In a groundbreaking development for addressing future viral pandemics, a multi-institutional team involving Lawrence Livermore National Laboratory researchers has successfully combined an artificial intelligence-backed platform with supercomputing to redesign and restore the effectiveness of antibodies whose ability to fight viruses has been compromised by viral evolution. The work was published in the journal Nature.
Simulated Chemistry: New AI Platform Designs Tomorrow’s Cancer Drugs
Researchers from University of California San Diego have developed a new AI tool to that generate new drug candidates for cancer, which could help streamline the typically laborious drug discovery process.
How Scientists Are Accelerating Chemistry Discoveries With Automation
Researchers have developed an automated workflow that could accelerate the discovery of new pharmaceutical drugs and other useful products. The new approach could enable real-time reaction analysis and identify new chemical-reaction products much faster than current laboratory methods.
Mimicking exercise with a pill
Could a pill replicate the benefits of exercise? Researchers have identified new compounds that seem to mimic some benefits of exercise in rodent cells. This discovery could help treat those with muscle wasting and other conditions. The scientists will present their results at ACS Spring 2024.
ReadCube Expands Its Award-Winning Literature Management Platform with the Launch of Literature Review
Digital Science is pleased to announce that ReadCube, an award-winning leader in literature management and full-text document delivery, has launched a new solution for research-driven organizations – known simply as Literature Review by ReadCube.
ReadCube Expands Its Award-Winning Literature Management Platform with the Launch of Literature Review
Digital Science is pleased to announce that ReadCube, an award-winning leader in literature management and full-text document delivery, has launched a new solution for research-driven organizations – known simply as Literature Review by ReadCube.
Device ‘smells’ seawater to discover, detect novel molecules
Researchers in ACS Central Science report a proof-of-concept device that “sniffs” seawater, trapping dissolved compounds for analyses. The team showed that the system could easily concentrate molecules that are present in underwater caves and holds promise for drug discovery in fragile ecosystems, including coral reefs.
Scientists build on artificial intelligence to create next-generation gastric acid treatment
Nagoya University researchers used AI to design and synthesize a new, highly effective gastric acid inhibitor, demonstrating the potential of AI in pharmaceutical development.
Broad-spectrum antiviral candidate targets dengue and SARS-CoV-2
A broad-spectrum antiviral drug candidate, 2-thiouridine, that targets positive-strand RNA viruses has been identified and characterized.
Icahn School of Medicine at Mount Sinai and the University of California San Diego Receive $8.5 Million Award to Establish a Data Integration Hub for NIH Common Fund Supported Programs
Researchers at the Icahn School of Medicine at Mount Sinai and the University of California San Diego have been awarded an $8.5 million grant to create a data integration hub aimed at accelerating novel therapeutics and cures for diseases within initiatives supported by the National Institutes of Health (NIH) Common Fund.
Emerging Drug Discovery Ecosystems in Virginia
A Special Issue of SLAS Discovery, Emerging Drug Discovery Ecosystems, is now available.
Mount Sinai Scientists Unlock Secrets of Red Blood Cell Transporter, Potentially Paving the Way for New Drugs
Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how it interacts with drugs.
Looking at the Latest in Life Sciences Discovery and Technology
The August 2023 issue of SLAS Technology, the open access journal emphasizing scientific and technical advances across the life sciences, is now available.
New Advancements in Assay Development Research
The July 2023 issue of SLAS Discovery, the open access journal focused on research progressing drug discovery, is now available.
AI brings hope for patients with lyosomal storage disease
Artificial intelligence is becoming increasingly important in drug discovery.
$11.7M from Department of Defense to fund research on common complication to traumatic brain injury
Researchers at the School of Science at IUPUI will lead grants to fund research toward an effective drug treatment for hydrocephalus, a condition commonly associated with complications from traumatic brain injury.
Announcing the SLAS Technology Editor’s Top 10 for 2023
The SLAS Technology Editor’s Top 10 for 2023 highlights technologies that address a broad range of unmet needs in both the laboratory and the clinic.
Using AI to create better, more potent medicines
While it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, a new study suggests that using generative artificial intelligence could vastly accelerate the drug-development process.
UC San Diego First to Test Cancer Drugs in Space Using Private Astronaut Mission
The latest space experiments from UC San Diego and Axiom Space will explore therapies for breast and colorectal cancer aboard the ISS, and monitor astronauts’ stem cell health over time.
Analyzing CAR-T Cells with Image Cytometry for Potential Solid Tumor Treatments
The April 2023 issue of SLAS Discovery contains six full-length articles and one mini-review covering high-throughput screening (HTS) for protease-inhibiting drugs, high-content phenotypic screening and other life sciences research.
Dana-Farber Cancer Institute receives $10 million gift from the Linde Family Foundation
The Linde Family Foundation has made a $10 million gift to launch the Center for Therapeutic Discovery at Dana-Farber Cancer Institute. This new center will be home to a new team devoted to the development of novel therapeutics for patients with rare and hard-to-treat cancers.
Fiery response: “Siglec-14” receptors on human macrophages detect carbon nanotubes and provoke inflammation, finds study
Carbon nanotubes (CNTs) have become a mainstay of the field of nanotechnology.
SLAS Discovery Highlights Protocols in Drug Discovery for March Special Issue
The March special issue of SLAS Discovery deviates from its traditional focus on assay technology, disease area or molecular target to introduce and explore protocol articles – the newly accepted article type for outlining detailed scientific methods and procedures.
Sanford Burnham Prebys researchers awarded $2.6M to discover pancreatic cancer drugs
Cosimo Commisso, Ph.D., and Susanne Heynen-Genel, Ph.D., have received a grant from the National Cancer Institute (NCI) to advance a new treatment approach for pancreatic cancer.
UC San Diego’s Astrobiotechnology Hub to Drive Drug Discovery in Space
UC San Diego’s new Astrobiotechnology Hub brings together leaders in academia, biotechnology and aerospace industries under a united mission to advance stem cell science and commercialization in space.
St. Jude approach prevents drug resistance and toxicity
Scientists at St. Jude Children’s Research Hospital showed an effective method to avoid activating a major cellular detoxification receptor to overcome drug resistance and toxicity.
First-of-its-kind instrument officially ushers in new era of X-ray science
Arizona State University has officially begun a new chapter in X-ray science with a newly commissioned, first-of-its-kind instrument that will help scientists see deeper into matter and living things. The device, called the compact X-ray light source (CXLS), marked a major milestone in its operations as ASU scientists generated its first X-rays on the night of Feb. 2.
Laboratory Automation and Life Sciences Research Conference Open to Media Registration: February 26-March 1, 2023 in San Diego
The Society for Laboratory Automation and Screening (SLAS) invites members of the press, science journalists and trade press to attend the SLAS2023 International Conference and Exhibition, the society’s annual flagship conference.
Artificial Intelligence Aids Discovery of Super Tight-Binding Antibodies
UC San Diego scientists developed an artificial intelligence tool that could accelerate the development of new high affinity antibody drugs.
A New Assay Screening Method Shows Therapeutic Promise for Treating Auto-Immune Disease
The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.
UC Irvine, UCLA researchers identify new therapeutic approach to prevent ARDS
A novel peptide designed by University of California, Irvine researchers has been found to suppress the damaging lung inflammation seen in acute respiratory distress syndrome, or ARDS. Their study, which appears in iScience, describes the first specific treatment designed to prevent the deadly disease, which can appear in patients with severe lung injury from infections with bacteria and viruses, like pneumonia, flu, respiratory syncytial virus (RSV) and COVID-19.
New Look at an Ancient Disease: Study Finds Novel Treatment Targets for Gout
UC San Diego scientists identify a new molecular model and potential therapeutic target for gout, the most common form of inflammatory arthritis.